SavedAdd your journal

Journals / Medical Network Klinik Bilimler ve Doktor / 2002 / Cilt: 8 - Sayı: 5

The relationship between the lipoprotein (a) level and severity of chronic liver disease

Kronik karaciğer parankim hastalarında lipoprotein (a)'nın karaciğer hasarı ile ilişkisi

H. Emre KAYA
Bülent ÖDEMİŞ
Z. Mesut Yalın KILIÇ
Osman YÜKSEL
Ertuğrul KAYAÇETİN
Pages
568–570
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: In that study it was found out that Lp(a) levels were decreasing while the severity of liver disease was increasing.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: In this study, we investigated the lipoprotein (a) levels of cirrhotic patients which had proven role in many physiologic and pathophysiologic events compared the levels with respect to the cirrhosis ethiology.
📊
Key Findings & Data:MATERIAL AND METHODS: Lp(a) levels measured in 22 patients of class Child A+B, and 28 patients of class Child C.
💡
Conclusion & Impact:CONCLUSION: In that study it was found out that Lp(a) levels were decreasing while the severity of liver disease was increasing.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Karaciğer sirozu · Karaciğer hastalıkları · Kronik hastalık

Abstract

OBJECTIVE: In this study, we investigated the lipoprotein (a) levels of cirrhotic patients which had proven role in many physiologic and pathophysiologic events compared the levels with respect to the cirrhosis ethiology. MATERIAL AND METHODS: Lp(a) levels measured in 22 patients of class Child A+B, and 28 patients of class Child C. RESULTS: We found out that Lp (a) levels seemed to be low. With respect to ethiology, there was no statistically difference. But when we compared child A and B group to child C patients there was statistically difference between them. CONCLUSION: In that study it was found out that Lp(a) levels were decreasing while the severity of liver disease was increasing. According to this results we believe that Lp(a) levels may be used as a predictor of severity of liver disease.

Özet

AMAÇ: Biz bu çalışmamızda organizmada pek çok fizyolojik ve patofizyolojik olayda rol oynadığı ispatlanmış olan lipoprotein (a)'nın siroz hastalarındaki serum konsantrasyonlarını saptamayı ve siroz etiyolojisi açısından Lp(a) düzeylerini kıyaslamayı amaçladık. GEREÇ VE YÖNTEM: Çalışmaya Child (A+B) grubuna 22 hasta, Child C grubuna 28 hasta ve kontrol grubuna 35 sağlıklı birey alındı. Bu hastalarda Lp(a) düzeyleri ölçüldü. BULGULAR: Sirozlu hastarda Lp(a) seviyelerini azalmış olarak bulduk. Sirozun etiyolojisine göre Lp(a) seviyelerinde istatistiksel olarak anlamlı bir farklılık yoktu. Ancak hastalığın şiddetini belirleyen Child-Pugh A ve B ile Child Pugh C sınıfları arasında anlamlı farklılık vardı. SONUÇ: Çalışmamızda, karaciğer hücre harabiyetinin şiddetinin artmasıyla Lp(a) seviyelerindeki azalmanın korele olduğunu saptadık ve Lp(a)'nın konsantrasyonlarındaki azalmanın karaciğer hücre harabiyetini gösterecek bir parametre olabileceği kanaatine vardık.

🔖

Cite This Article

KAYA, H. E., ÖDEMİŞ, B., KILIÇ, Z. M. Y., YÜKSEL, O., KAYAÇETİN, E. (2002). The relationship between the lipoprotein (a) level and severity of chronic liver disease. Medical Network Klinik Bilimler ve Doktor, Cilt: 8 - Sayı: 5, 568–570. https://ajindex.com/articles/278731

References (8)

  1. Scanu AM. And Fless GM.: Lipoprotein (a): Heterogeneity and biological prevalance. J Clin Invest 1990; 85:1709-15.
  2. Morrisett J, Guabatz D, Knapp W, Guavera RD. Lipoprotein (a) structural properties of apo (a): A major apoprotein of human lipoprotein (a). Scanu; AM. Academic Press New York, 1990; 53-74 Scanu AM. Lipoprotein (a). A genetic risk factor for premature coronary heart disease. JAMA 1992; 267:3326-9. Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 1993; 59:369-82.
  3. Miles LA, Plow EF. Lp(a): An interlooper into fibrinolytic system. Thromb Haemost 1990; 63:311-35.
  4. Mann W A, Kraft HG, Reder DJ. Human in-vivo catabolism of Lp(a). Circulation 1989; 80:11-181 (abstr). Kraft HG, Menzel H, Hoppicher F, Vogel W, Utermann G. Changes of genetic epolipoprotein phenotypes caused by liver transplantations: Implications for apolipoprotein synthesis. J Clin Invest 1989; 83:137-42.
  5. Sandholzer C, Hallman DM, Saha N, Siguradason G, Luckner C, Cosaszar A, Boerwinkle E, Utermann G. Effect of apolipoprotein (a) size polymorphism on Lipoprotein (a) concentration in seven ethnic groups. Hum Genet 1991; 86: 607-14.
  6. Hoffman SL, Eaton DL, Brown MS, McChonaty WJ, Goldstein JL, Hamme RE. Over expression of human low density lipoprotein recerptors leads to accelerated catabolism of Lp(a) in transgenic mice. J Clin Invest. 1990; 85:1542-7.
  7. Felly J, Barry M, Kealing PW, Weir DG, Cooke T. Lipoprotein (a) in cirrhosis. BMJ 1992; 304:545-6.
  8. Scmidt H, Wagner S, Kolm R, Manns M. Lipoprotein (a) in cirrhosis. BMJ 1992; 304:1180. Utermann G, Kraft HG: Lipoprotein (a) in cirrhosis. BMJ 1992; 305:185. Van Wersch JM. The behaviour of lipoprotein (a) in patients with various diseases. Scandinavian Journal of Clinical and Laboratory Investigation. 1994; 54:559-62. Fondazione AC. Relationship between lipoprotein (a) levels in serum and some indices of protein synthesis in liver cirrhosis. Clinical Chimica Acta. 1994; 224:125-9.